How should an acute exacerbation of giant cell arteritis be treated in a patient over 50 years old who is already on steroids and now has worsening headache, scalp tenderness, jaw claudication, or visual changes?

Giant Cell Arteritis Exacerbation Management

For a patient over 50 with GCA already on steroids who develops worsening symptoms (headache, scalp tenderness, jaw claudication, or visual changes), immediately increase oral glucocorticoids to 40-60 mg/day prednisone-equivalent and add tocilizumab as adjunctive therapy. 1, 2

Immediate Assessment and Action

When a patient on maintenance steroids develops new or worsening GCA symptoms, this represents a major relapse requiring urgent intervention:

Visual Symptoms (Medical Emergency)

If the patient presents with any visual symptoms (diplopia, blurring, amaurosis fugax, or vision loss):

• Consider IV methylprednisolone 0.25-1 g/day for 3 days before transitioning to high-dose oral prednisone (60 mg/day preferred for visual symptoms) 1
• However, do not delay oral glucocorticoid treatment while arranging IV access or transfer 1
• The evidence for IV pulse therapy is limited quality, and recent data suggests it may not prevent bilateral vision loss better than immediate high-dose oral steroids 3, 4

Critical caveat: IV methylprednisolone carries significantly higher risk of complications (31.8% vs 10.7% in first month) including new-onset diabetes (OR 2.59-3.30) without clear benefit for visual recovery 3, 4. For patients with high glucocorticoid-related risk factors, proceed directly with oral prednisone 60 mg/day.

Non-Visual Cranial Symptoms

For relapse with headache, jaw claudication, or scalp tenderness without visual involvement:

• Increase oral prednisone to 40-60 mg/day 1
• Add a glucocorticoid-sparing agent immediately (see below)

Glucocorticoid-Sparing Therapy

The 2018 EULAR guidelines and 2021 ACR guidelines both recommend adding immunosuppressive therapy for relapses on moderate-to-high dose steroids 1, 2:

First-Line: Tocilizumab

• Tocilizumab 162 mg subcutaneously weekly is the preferred adjunctive agent 1, 2
• Allows faster glucocorticoid taper (to <5 mg at 6 months vs 1 year with steroids alone) 1
• Reduces relapse rates from 34-75% to significantly lower levels 1
• Recent data shows tocilizumab with only 8 weeks of prednisone achieved 77% sustained remission at 52 weeks 5

Alternative: Methotrexate

• If tocilizumab unavailable or contraindicated, use methotrexate 15-25 mg weekly 1, 2
• Less effective than tocilizumab for cranial ischemic symptoms 2

Tapering Strategy After Relapse Control

Once remission is re-achieved:

• Taper to 15-20 mg/day within 2-3 months 1
• Then taper to ≤5 mg/day after 1 year 1
• With tocilizumab, can achieve more aggressive taper (to <5 mg at 6 months) 1
• Avoid rapid tapers below 5 mg/day - this is when relapse risk increases dramatically 1

Additional Considerations

Antiplatelet Therapy

• Add aspirin if critical or flow-limiting involvement of vertebral or carotid arteries 6, 2
• Routine antiplatelet therapy is no longer recommended unless indicated for other reasons 1

Monitoring

• Check ESR/CRP, but do not escalate therapy for elevated inflammatory markers alone without clinical symptoms 2, 7
• Isolated marker elevation may reflect infection or other conditions 7

Common Pitfall

Do not mistake glucocorticoid withdrawal symptoms, osteoarthritis, or unrelated conditions for GCA relapse 7. Confirm true disease activity with both clinical symptoms AND inflammatory markers before escalating therapy.

Duration of Treatment

Most patients require 2 years or more of total glucocorticoid therapy 1. With tocilizumab, some patients may achieve sustained remission with shorter courses (12 months tocilizumab + 8 weeks prednisone showed promise) 5.